BIO-TECHNE Corp OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax
BIO-TECHNE Corp (TECH) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax of -$32.08 million for the 3-month period ending 2016-03-31, per its 10-Q filed 2016-05-10.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax · last filed 2016-05-10
- BIO-TECHNE Corp oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2016-03-31 was -$32.08M, a 1187.86% decline year-over-year.
- BIO-TECHNE Corp oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2015-12-31 was $9.60M, a 33.04% decline year-over-year.
- BIO-TECHNE Corp oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2015-09-30 was -$10.13M.
- BIO-TECHNE Corp oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2015-06-30 was $2.51M.
- BIO-TECHNE Corp oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2015 was $11.31M.
- BIO-TECHNE Corp oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2014 was -$35.76M.
- BIO-TECHNE Corp oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2013 was -$3.68M, a 108.80% decline from fiscal 2012.
- BIO-TECHNE Corp oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2012 was $41.87M.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 12 month |
|---|---|---|---|---|
| 2016-03-31 | -$32.08M 10-Q · filed 2016-05-10 | -$22.48M derived: sum of 2 quarters · filed 2016-05-10 | -$32.60M 10-Q · filed 2016-05-10 | -$30.10M derived: sum of 4 quarters · filed 2016-05-10 |
| 2015-12-31 | $9.60M 10-Q · filed 2016-02-09 | -$523.00K 10-Q · filed 2016-02-09 | $1.99M derived: sum of 3 quarters · filed 2016-02-09 | $4.93M derived: sum of 4 quarters · filed 2016-05-10 |
| 2015-09-30 | -$10.13M 10-Q · filed 2015-11-09 | -$7.62M derived: sum of 2 quarters · filed 2015-11-09 | -$4.67M derived: sum of 3 quarters · filed 2016-05-10 | $9.67M derived: sum of 4 quarters · filed 2016-05-10 |
| 2015-06-30 | $2.51M derived: 10-K 12 month − 10-Q 9 month · filed 2015-08-31 | $5.46M derived: sum of 2 quarters · filed 2016-05-10 | $19.80M derived: sum of 3 quarters · filed 2016-05-10 | $11.31M 10-K · filed 2015-08-31 |
| 2015-03-31 | $2.95M 10-Q · filed 2016-05-10 | $17.29M derived: sum of 2 quarters · filed 2016-05-10 | $8.80M 10-Q · filed 2016-05-10 | $3.48M derived: sum of 4 quarters · filed 2016-05-10 |
| 2014-12-31 | $14.34M 10-Q · filed 2016-02-09 | $5.85M 10-Q · filed 2016-02-09 | $532.00K derived: sum of 3 quarters · filed 2016-02-09 | $5.84M derived: sum of 4 quarters · filed 2016-02-09 |
| 2014-09-30 | -$8.49M 10-Q · filed 2015-11-09 | -$13.81M derived: sum of 2 quarters · filed 2015-11-09 | -$8.50M derived: sum of 3 quarters · filed 2015-11-09 | -$7.47M derived: sum of 4 quarters · filed 2015-11-09 |
| 2014-06-30 | -$5.32M derived: 10-K 12 month − 10-Q 9 month · filed 2015-08-31 | -$8.00K derived: sum of 2 quarters · filed 2015-08-31 | $1.02M derived: sum of 3 quarters · filed 2015-08-31 | -$35.76M 10-K · filed 2015-08-31 |
| 2014-03-31 | $5.31M 10-Q · filed 2015-05-11 | $6.33M derived: sum of 2 quarters · filed 2015-05-11 | -$30.44M 10-Q · filed 2015-05-11 | -$29.42M derived: sum of 4 quarters · filed 2015-08-31 |
| 2013-12-31 | $1.02M 10-Q · filed 2015-02-09 | -$35.75M 10-Q · filed 2015-02-09 | -$34.73M derived: sum of 3 quarters · filed 2015-08-31 | -$22.88M derived: sum of 4 quarters · filed 2015-08-31 |
| 2013-09-30 | -$36.78M 10-Q · filed 2014-11-10 | -$35.75M derived: sum of 2 quarters · filed 2015-08-31 | -$23.90M derived: sum of 3 quarters · filed 2015-08-31 | -$26.90M derived: sum of 4 quarters · filed 2015-08-31 |
| 2013-06-30 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2015-08-31 | $12.87M derived: sum of 2 quarters · filed 2015-08-31 | $9.88M derived: sum of 3 quarters · filed 2015-08-31 | -$3.68M 10-K · filed 2015-08-31 |
| 2013-03-31 | $11.85M 10-Q · filed 2014-05-12 | $8.85M derived: sum of 2 quarters · filed 2014-05-12 | -$4.71M 10-Q · filed 2014-05-12 | $13.29M derived: sum of 4 quarters · filed 2014-08-29 |
| 2012-12-31 | -$3.00M 10-Q · filed 2014-02-04 | -$16.56M 10-Q · filed 2014-02-04 | $1.43M derived: sum of 3 quarters · filed 2014-08-29 | $25.32M derived: sum of 4 quarters · filed 2014-08-29 |
| 2012-09-30 | -$13.56M 10-Q · filed 2013-11-12 | $4.43M derived: sum of 2 quarters · filed 2014-08-29 | $28.32M derived: sum of 3 quarters · filed 2014-08-29 | $28.34M derived: sum of 4 quarters · filed 2014-08-29 |
| 2012-06-30 | $17.99M derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-29 | $41.88M derived: sum of 2 quarters · filed 2014-08-29 | $41.90M derived: sum of 3 quarters · filed 2014-08-29 | $41.87M 10-K · filed 2014-08-29 |
| 2012-03-31 | $23.89M 10-Q · filed 2013-05-10 | $23.91M derived: sum of 2 quarters · filed 2013-05-10 | $23.88M 10-Q · filed 2013-05-10 | |
| 2011-12-31 | $21.00K 10-Q · filed 2013-02-11 | -$7.00K 10-Q · filed 2013-02-11 | ||
| 2011-09-30 | -$28.00K 10-Q · filed 2012-11-09 | |||
| 2011-06-30 | -$85.00K 10-K · filed 2013-08-29 | |||
| 2010-06-30 | $175.00K 10-K · filed 2012-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |